Clinical Trials Logo

Filter by:
NCT ID: NCT01111461 Completed - Endometrial Cancer Clinical Trials

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Start date: March 2010
Phase: Phase 2
Study type: Interventional

To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .

NCT ID: NCT01111318 Completed - Healthy Clinical Trials

Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function

Start date: July 2010
Phase: Phase 1
Study type: Interventional

The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.

NCT ID: NCT01108809 Completed - Hypertension Clinical Trials

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Start date: April 2010
Phase: N/A
Study type: Observational

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

NCT ID: NCT01106651 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.

NCT ID: NCT01106014 Completed - Clinical trials for Pulmonary Arterial Hypertension

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

GRIPHON
Start date: December 1, 2009
Phase: Phase 3
Study type: Interventional

The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.

NCT ID: NCT01105546 Active, not recruiting - Clinical trials for Hemophilia A With Inhibitors

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

ENJOIH
Start date: December 2010
Phase: Phase 2
Study type: Interventional

The study evaluates the efficacy and safety of a prophylactic treatment with recombinant activated FVII in reducing the frequency of joint bleeds and the development of joint damage in children with hemophilia A who develop high-titer inhibitors.

NCT ID: NCT01104792 Completed - Schizophrenia Clinical Trials

Long-term Study of Cariprazine in Patients With Schizophrenia

Start date: May 31, 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.

NCT ID: NCT01104766 Completed - Schizophrenia Clinical Trials

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Start date: April 23, 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.

NCT ID: NCT01103804 Completed - Clinical trials for Gastroesophageal Reflux

Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment

Start date: March 2010
Phase: N/A
Study type: Observational

The primary objective of the study is to describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(using GerdQ questionnaire). The secondary objectives are: to measure the response at the current treatment after a 4-week period of systematic treatment and to identify the percentage of patients which require alterations of their treatment (GerdQ questionnaire)

NCT ID: NCT01100502 Completed - Disease, Hodgkin Clinical Trials

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Start date: April 30, 2010
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).